News

Ipca Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 13 August 2026.

The board of Ipca Laboratories at its meeting held on 26 June 2026 has approved the scheme of amalgamation of Krebs Biochemicals & Industries (Transferor Company) with the company (Transferee Company) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

Ipca Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 6 per equity Share (i.e. 600%) , subject to the approval of the shareholders.

Net profit of Ipca Laboratories rose 340.98% to Rs 299.07 crore in the quarter ended March 2026 as against Rs 67.82 crore during the previous quarter ended March 2025. Sales rose 6.31% to Rs 2388.48 crore in the quarter ended March 2026 as against Rs 2246.69 crore during the previous quarter ended March 2025.For the full year,net profit rose 54.69% to Rs 1141.12 crore in the year ended March 2026 as against Rs 737.68 crore during the previous year ended March 2025. Sales rose 7.91% to Rs 9646.33 crore in the year ended March 2026 as against Rs 8939.59 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2388.482246.69 6 9646.338939.59 8 OPM %20.2619.09 -20.5119.31 - PBDT557.41433.17 29 2077.071734.01 20 PBT450.27333.05 35 1658.951336.19 24 NP299.0767.82 341 1141.12737.68 55 Powered by Capital Market - Live News

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2026.